Sanborn and Gaffar Share Clinical and Economic Treatment Insights in NSCLC


In our exclusive interview, Dr. Sanborn and Dr. Gaffar share insight into the clincal and economic considerations for treatment in advanced NSCLC.

Welcome to OncLive On Air! I’m your host today, Caroline Seymour.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Bristol Myers Squibb, we had the pleasure of speaking with Rachel E. Sanborn, MD, co-director of the Thoracic Oncology Program at the Robert W. Franz Cancer Research Center and Earle A. Chiles Research Institute at Providence Cancer Institute, and Yousuf A. Gaffar, MD, a medical oncologist at Maryland Oncology Hematology, to discuss the cost of care in advanced non–small cell lung cancer (NSCLC), frontline treatment options for patients without driver mutations, and optimal adverse effect management strategies for approved regimens.

In our exclusive interview, Sanborn and Gaffar shared insight into the clincal and economic considerations for treatment in advanced NSCLC.

Related Videos
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Saad J. Kenderian, MB, CHB
Jaime Schneider, MD, PhD
Benjamin Creelan, MD
Neel P. Chudgar, MD
Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine
Raj Singh, MD
Arya Amini, MD
Vlad Gabriel Zaha, MD, PhD